ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Aurobindo To Sell Unit To Sinopharm

by Ann M. Thayer
January 17, 2011 | APPEARED IN VOLUME 89, ISSUE 3

India-based Aurobindo Pharma will sell Aurobindo Bio-Pharma, its Datong, China, subsidiary, to China National Pharmaceutical (Sinopharm). The subsidiary, which has incurred losses, makes the penicillin derivative 6-APA. Sinopharm will acquire a 51% stake and then raise it to 80.5% by investing to relocate a plant, as required by the local Chinese government, and to enhance capacity and downstream products. Aurobindo says it has moved away from active pharmaceuticals and is now emphasizing its formulation business.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment